Rising Prevalence of Drug-Resistant Epilepsy
In African neurology practices, drug-resistant epilepsy cases are frequently recognized after numerous rounds of anticonvulsant medication optimization that have taken place in routine neurology or even general practice environments. The referral process for surgery or neuromodulation often occurs at a late stage, largely due to fragmented referral pathways and limited access to dedicated epilepsy monitoring units.
In this context, decisions become more multidisciplinary once pharmacologic management fails, but in most African tertiary care centers, neuromodulation approaches are discussed only after exhausting all medication attempts and managing comorbidities. Consequently, device-based therapy is often positioned as a late-stage, advanced option within a constrained neurosurgical workflow, heavily influenced by available resources and operating theater prioritization.
On the other hand, the use of invasive neurostimulation devices is becoming increasingly concentrated in private neurology clinics and selected teaching hospitals, where clinicians gain familiarity with these technologies through gradual clinical exposure and overseas training opportunities. In parallel, device manufacturers often engage hospitals through a demonstration-led adoption model rather than broad, system-wide distribution.
Expansion in Treatment-Resistant Depression
Within psychiatric care pathways in African urban centers, treatment-resistant depression is managed through layered escalation frameworks, where pharmacological switching is followed by structured intensification of psychotherapy before any consideration of device-based neuromodulation. Clinical teams typically depend on longitudinal observation within outpatient psychiatry units to assess suitability for interventions beyond medication-based strategies.
Driven by the growing acceptance of neuromodulation in psychiatric practice, clinicians in selected African referral hospitals are beginning to integrate noninvasive and invasive stimulation techniques into stepwise treatment plans, particularly for patients with recurrent non-response to antidepressant regimens. However, adoption remains influenced by protocol conservatism and the requirement for multidisciplinary psychiatric and neurological consensus before proceeding.
In private mental health networks and specialized neurology-psychiatry crossover clinics, device-based interventions for treatment-resistant depression are being introduced through carefully selected patient cohorts, often prioritizing individuals with stable clinical histories and documented pharmacotherapy resistance. Follow-up structures emphasize programming adjustments, side-effect monitoring, and caregiver engagement, while manufacturers support adoption through clinician training workshops and limited-site pilot implementations that emphasize procedural familiarity over scale.
